Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 1, 2003, Pages 212-218

  Liu, Yuxin ^a   Qin, Liya ^a   Li, Guorong ^a   Zhang, Wei ^a   An, Lijia ^b   Liu, Bin ^a   Hong, Jau Shyong ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AMYLOID BETA PROTEIN; DEXTROMETHORPHAN; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID; LIPOPOLYSACCHARIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; XANTHINE OXIDASE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BRAIN PROTECTION; CELL ACTIVATION; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; EMBRYO; ENCEPHALITIS; MICROGLIA; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; AMYLOID BETA-PROTEIN; ANIMALS; CELLS, CULTURED; DEXTROMETHORPHAN; DRUG INTERACTIONS; INFLAMMATION; LIPOPOLYSACCHARIDES; MICROGLIA; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, INBRED F344; RECEPTORS, DOPAMINE; SUPEROXIDES; XANTHINE; XANTHINE OXIDASE;

EID: 0037381043     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.043166     Document Type: Article

References (57)

1. Aloisi F (1999) The role of microglia and astrocytes in CNS immune surveillance and immunopathology. Adv Exp Med Biol 468:123-133.
2. Araki E, Forster C, Dubinsky JM, Ross ME, and Iadecola C (2001) Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity. Stroke 32:2370-2375.
3. Beckman JS, Beckman TW, Chen J, Marshall PA, and Freeman BA (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87:1620-1624.
4. 3H] MK-801 binding to N-methyl-D-aspartate receptors in cultured rat cerebellar granule neurons and involvement in glutamate-mediated toxicity. J Biochem Toxicol 11:217-226.
5. Boje KM and Arora PK (1992) Microglia-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res 587:250-256.
6. Britton P, Lu XC, Laskosky MS, and Tortella FC (1997) Dextromethorphan protects against cerebral injury following transient, but not permanent, focal ischemia in rats. Life Sci 60:1729-1740.
7. Bronstein DM, Perez-Otano I, Sun V, Mullis-Sawin SB, Chan J, Wu GC, Hudson PM, Kong LY, Hong JS, and McMillian MK (1995) Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res 704:112-116.
8. Cadet JL and Brannock C (1998) Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 32:117-131.
9. Castano A, Herrera AJ, Cano J, and Machado A (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 70:1584-1592.
10. Chang RC, Rota C, Glover RE, Mason RP, and Hong JS (2000) A novel effect of an opioid receptor antagonist, naloxone, on the production of reactive oxygen species by microglia: a study by electron paramagnetic resonance spectroscopy. Brain Res 854:224-229.
11. Chao CC, Hu S, Ehrlich L, and Peterson PK (1995) Interleukin-1 and tumor necrosis factor-α synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain Behav Immun 9:355-365.
12. Chao CC, Hu S, Moliter TW, Shaskan EG, and Peterson PK (1992) Activated microglia mediate cell injury via a nitric oxide mechanism. J Immunol 149:128-1232.
13. Choi DW (1987) Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity. Brain Res 403:333-336.
14. Craviso GL and Musacchio JM (1983a) High-affinity dextromethorphan binding sites in guinea pig brain. I. Initial characterization. Mol Pharmacol 23:619-628.
15. Craviso GL and Musacchio JM (1983b) High-affinity dextromethorphan binding sites in guinea pig brain. II. Competition experiments. Mol Pharmacol 23:629-640.
16. Dawson VL, Brahmbhatt HP, Mong JA, and Dawson TM (1994) Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology 33:1425-1430.
17. DeCoster MA, Klette KL, Knight ES, and Tortella FC (1995) Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res 671:45-53.
18. Dickson DW, Lee SC, Mattiace LA, Yen SH, and Brosnan C (1993) Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7:75-83.
19. Estevez AG and Jordan J (2002) Nitric oxide and superoxide, a deadly cocktail. Ann NY Acad Sci 962:207-211.
20. Floyd RA (1999) Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic Biol Med 26:1346-1355.
21. Gayle DA, Ling Z, Tong C, Landers T, Lipton JW, and Carvey PM (2002) Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-α, interleukin-1β and nitric oxide. Brain Res Dev Brain Res 133:27-35.
22. Gao HM, Hong JS, Zhang WQ, and Liu B (2002a) Distinct Role for Microglia in Rotenone-induced Degeneration of Dopaminergic Neurons. J Neurosci 22:782-790.
23. Gao HM, Jiang J, Wilson B, Zhang WQ, Hong JS, and Liu B (2002b) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81:1285-1297.
24. George CP, Goldberg MP, Choi DW, and Steinberg GK (1988) Dextromethorphan reduces neocortical ischemic neuronal damage in vivo. Brain Res 440:375-379.
25. Giulian D (1999) Microglia and the immune pathology of Alzheimer disease. Am J Hum Genet 65:13-18.
26. Greenamyre JT, MacKenzie GM, Peng T-I, and Stephans SE (1999) Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp 66:85-97.
27. Haberecht MF, Mitchell CK, Lo GJ, and Redburn DA (1997) N-Methyl-D-aspartate-mediated glutamate toxicity in the developing rabbit retina. J Neurosci Res 47:416-426.
28. Jenner P and Olanow W (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47:S161-S170.
29. Jeohn GH, Kim WG, and Hong JS (2000) Time dependency of the action of nitric oxide in lipopolysaccharide-interferon-γ-induced neuronal cell death in murine primary neuron-glia co-cultures. Brain Res 880:173-177.
30. Jeohn G-H, Kong L-Y, Wilson B, Hudson P, and Hong J-S (1998) Synergistic neurotoxic effects of combined treatments with cytokines in murine primary mixed neuron/glia cultures. J Neuroimmunol 85:1-10.
31. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, and Hong J-S (2000) Regional difference in the susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20:6309-6316.
32. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19:312-318.
33. Lesage AS, De Loore KL, Peeters L, and Leysen JE (1995) Neuroprotective sigma ligands interfere with the glutamate-activated NOS pathway in hippocampal cell culture. Synapse 20:156-164.
34. Ling Z, Gayle DA, Mas Y, Lipton JW, Tong CW, Hong JS, and Carvey PM (2002) In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord 17:116-124.
35. Liu B, Du L, and Hong JS (2000a) Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Phar Exp Ther 293:607-617.
36. Liu B, Gao HM, Wang J-Y, Jeohn G-H, Cooper CL, and Hong JS (2002a) Role of nitric oxide in inflammation-mediated neurodegeneration. Ann NY Acad Sci 962:256-263.
37. Liu B and Hong JS (2003) Role of microglia in inflammation-mediated neurodegenerative diseases: study of mechanism and strategies for therapeutic intervention. J Pharmacol Exp Ther 304:1-7.
38. Liu B, Jiang JW, Wilson BC, Du L, Yang SN, Wang JY, Wu GC, Cao XD, and Hong JS (2000b) Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther 295:125-132.
39. Liu YX, Qin L, Wilson BC, An L, Hong JS, and Liu B (2002b) Inhibition by naloxone stereoisomers of β-amyloid peptide (1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. J Pharmacol Exp Ther 302:1212-1219.
40. Lu X, Bing G, and Hagg T (2000) Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats. Neuroscience 97:285-291.
41. McCord JM and Fridovich I (1968) The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem 243:5753-5740.
42. McGeer PL, Itagaki S, Boyes BE, and McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285-1291.
43. McGeer PL and McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzeimer and other neurodegenerative diseases. Brain Res Brain Res Rev 21:195-218.
44. McGuire SO, Ling ZD, Lipton JW, Sortwell CE, Collier TJ, and Carvey PM (2002) Tumor necrosis factor α is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol 169:219-230.
45. Monyer H and Choi DW (1988) Morphinans attenuate cortical neuronal injury induced by glucose deprivation in vitro. Brain Res 446:144-148.
46. Obrenovitch TP, Urenjak J, Zilkha E, and Jay TM (2000) Excitotoxicity in neurological disorders-the glutamate paradox. Int J Dev Neurosci 18:281-287.
47. Olanow CW and Tatton WG (1999) Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22:123-144.
48. Peskin AV and Winterbourn CC (2000) A microtiter plate assay for superoxide dismutase using a water-soluble tetrazolium salt (WST-1). Clin Chim Acta 293:157-166.
49. Prince DA and Feeser HR (1988) Dextromethorphan protects against cerebral infarction in a rat model of hypoxia-ischemia. Neurosci Lett 85:291-296.
50. Qin L, Liu YX, Cooper CL, Liu B, Wilson BC, and Hong JS (2002) Microglia enhance β-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem 83:973-983.
51. Simpkins CO, Ives N, Tate E, and Johnson M (1985) Naloxone inhibits superoxide release from human neutrophils. Life Sci 37:1381-1386.
52. Steinberg GK, George CP, DeLaPaz R, Shibata DK, and Gross T (1988) Dextromethorphan protects against cerebral injury following transient focal ischemia in rabbits. Stroke 19:1112-1118.
53. Tan AS and Berridge MV (2000) Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents. J Immunol Meth 238:59-68.
54. Tortella FC, Pellicano M, and Bowery NG (1989) Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 10:501-507.
55. Tortella FC, Britton P, Williams A, Lu XC, and Newman AH (1999) Neuroprotection (focal ischemia) and neurotoxicity (electroencephalographic) studies in rats with AHN649, a 3-amino analog of dextromethorphan and low-affinity N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther 291:399-408.
56. Wang JP, Hsu MF, Raung SL, Chang LC, Tsao LT, Lin PL, and Chen CC (1999) Inhibition by magnolol of formylmethionyl-leucyl-phenyl alanine-induced respiratory burst in rat neutrophils. J Pharm Pharmacol 51:285-294.
57. Xie Z, Wei M, Morgan TE, Fabrizio P, Han D, Finch CE, and Longo VD (2002) Peroxynitrite mediates neurotoxicity of amyloid β-peptide1-42-and lipopolysaccharide-activated microglia. J Neurosci 22:3484-3492.